Androgen receptor splice variants (AR-Vs) are expressed in castration-resistant prostate cancer (CRPC) and are constitutively active. AR-Vs are induced by several mechanisms, including androgen ...

The androgen receptor in prostate cancer cells can activate different sets of genes depending on whether it binds with an androgen hormone or an antiandrogen drug, according to a new study. The ...

Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration ...

Mitochondrial localization, import and mitochondrial function of the androgen receptor. Journal of Biological Chemistry , 2019; jbc.RA118.006727 DOI: 10.1074/jbc.RA118.006727 Cite This Page : ...

An alternative treatment approach for AR-V7–positive patients would be to design agents targeting the N-terminal domain of the androgen receptor, 22–24 which would theoretically inhibit both ...

Estrogen receptor alpha (ER), progesterone receptor (PR), and androgen receptor (AR) have been implicated in the pathophysiology of other cancer types.

In contrast to other steroid receptors, such as ERα, the activation function of androgen receptor (AR) is largely dependent on its ligand-independent AF-1 located in its N-terminal domain (NTD).

Background: AR ligand binding domain (LBD) activating somatic point mutation is a known mechanism of resistance to androgen-receptor signaling inhibitor (ARSI) treatment in mCRPC, leading to a ...

“The role of the androgen receptor (AR) in estrogen receptor (ER)-α-positive breast cancer is controversial, constraining implementation of AR-directed therapies,” the researchers wrote.

A protein called the androgen receptor normally functions to guide the development of the prostate—signaling the cells to stop growing, act as normal prostate cells and maintain a healthy state.

-- In Phase 2 study, enobosarm, an oral selective androgen receptor (AR) agonist, had the most significant antitumor effects in heavily pretreated AR+ER+ metastatic breast cancer subjects with ≥ ...